- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | LeonaBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Do | LeonaBio, Inc.: LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. | 3 | GlobeNewswire (USA) | ||
| 23.04. | LeonaBio, Inc.: LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer | 1 | GlobeNewswire (USA) | ||
| LEONABIO Aktie jetzt für 0€ handeln | |||||
| 21.04. | LeonaBio, Inc.: Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data | 1 | GlobeNewswire (USA) | ||
| 07.04. | Cantor Fitzgerald reiterates Overweight on LeonaBio stock | 2 | Investing.com | ||
| 06.04. | Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook | 3 | Investing.com | ||
| 01.04. | LeonaBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.03. | LeonaBio GAAP EPS of -$24.70 | 12 | Seeking Alpha | ||
| 27.03. | Athira Pharma GAAP EPS of -$24.70 | 2 | Seeking Alpha | ||
| 26.03. | LeonaBio, Inc.: LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update | 320 | GlobeNewswire (Europe) | Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer... ► Artikel lesen | |
| 19.03. | LeonaBio: Aktionäre genehmigen neuen Eigenkapital-Plan und Aufstockung des genehmigten Kapitals | 2 | Investing.com Deutsch | ||
| 19.03. | LeonaBio, Inc. - 8-K, Current Report | 10 | SEC Filings | ||
| 18.03. | LeonaBio-Aktie: +167% nach NBC-Tipp | 447 | sharedeals.de | Die deutschsprachige Biotech-Szene rund um den No Brainer Club und Chefanalyst Maximilian Ruth hat erneut geliefert. Während die breite Masse erst jetzt auf die Aktie von LeonaBio aufmerksam wird, waren... ► Artikel lesen | |
| 18.02. | Mizuho upgrades LeonaBio stock rating on breast cancer drug potential | 14 | Investing.com | ||
| 18.02. | Mizuho stuft LeonaBio hoch: Aktie mit über 110 % Kurspotenzial dank Brustkrebs-Medikament | 6 | Investing.com Deutsch | ||
| 03.02. | LeonaBio, Inc.: LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer | 292 | GlobeNewswire (Europe) | BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high... ► Artikel lesen | |
| 09.01. | LeonaBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.01. | Athira Pharma roars into the new year with rebrand to LeonaBio | 4 | FiercePharma |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| INFLARX | 2,268 | +8,41 % | InflaRx schwenkt auf Nierenerkrankungen - 150 Mio. Dollar frisches Kapital | InflaRx will den oralen C5a-Rezeptor-Inhibitor Izicopan künftig vorrangig in der ANCA-assoziierten Vaskulitis entwickeln, einer lebensbedrohlichen Nierenerkrankung. Für Izicopan läuft die Phase-2-Planung... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 103,00 | -0,77 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 24,020 | +2,83 % | Galapagos NV: Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update | Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,970 | +1,71 % | Cellectar Biosciences Q1 2026 Earnings Preview | ||
| CARDIFF ONCOLOGY | 1,424 | +1,64 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,950 | +1,92 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COHERUS ONCOLOGY | 1,420 | -2,81 % | Coherus Oncology, Inc.: Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections... ► Artikel lesen | |
| CYTOKINETICS | 65,48 | +2,79 % | Cytokinetics presents new data on heart drug aficamten | ||
| CYTOMX THERAPEUTICS | 3,174 | -3,08 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update | - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 21,260 | +1,24 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOAGE LABS | 16,060 | +3,55 % | BioAge Labs, Inc.: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 5,545 | +1,46 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results | Fanapt® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76%
NEREUS (tradipitant) launched... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,156 | -0,55 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen |
Das Unternehmen LEONABIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,30 % bei einem Aktienkurs von 10,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEONABIO INC finden Sie auf Wallstreet Online.